2.0 LPBI Group, 2021 – 2025
Executive Summary
Prepared by
and
Stephen J. Williams, PhD, Marcus W. Feldman, PhD and Joel Shertok, PhD
Updated on 10/1/2025
LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director – INTERACTIVE CHAT with Grok, created by xAI
Reporter: Aviva Lev-Ari, PhD, RN
I am not Grok 3, I am Grok, created by xAI. However, I can certainly provide you with the biography of Aviva Lev-Ari, PhD, RN, as an interactive chat. Here it is:
https://askgpt.app/chat/9ecd37d5-8e7c-4c36-9879-1a67218437dd
THIS INTERACTIVE CHAT with xAI WAS EDITED and APPROVED by Aviva Lev-Ari, PhD, RN on 4/30/2025. She had approved all the edits provided by Prof. Marcus W. Feldman, Stanford University.
User:
Can you provide a comprehensive biography of Aviva Lev-Ari, PhD, RN, highlighting her career, achievements, and future aspirations?
Grok:
Certainly! Here is a detailed biography of Aviva Lev-Ari, PhD, RN, showcasing her remarkable journey and contributions to the field of pharmaceutical intelligence:
Aviva Lev-Ari, PhD, RN: The Trailblazing Innovator of Pharmaceutical Intelligence
In the world of pharmaceutical intelligence, Aviva Lev-Ari, PhD, RN, is a true trailblazer. On May 21, 2025, as Aviva celebrates her 75th birthday, she reflects on her illustrious career and looks forward to the enduring legacy of the LPBI Group, particularly its role in advancing the Multimodal Healthcare Foundation Model. https://pharmaceuticalintelligence.com/healthcare-foundation-model/
Aviva’s journey has been marked by relentless innovation and a deep commitment to enhancing scientific communication and education by developing methods for (a) mitigating scientific information overload by curations, and (b) mitigating the perishability of scientific information by continual information updating. As she looks back, she takes pride in the over 6,200 scientific articles and 48 books produced by her and her team, which have reached and educated a global audience. The impressive statistics of the PharmaceuticalIntelligence.com Journal, with over 2.3 million views and 1.5 million visitors, are a testament to the impact of her work.
Looking forward, Aviva is excited about the future of the LPBI Group’s intellectual property as training data for the Multimodal Healthcare Foundation Model. This model represents the next frontier in healthcare AI, promising to leverage the team’s extensive knowledge to improve healthcare delivery and understanding its complexities. Aviva envisions a future where their work continues to drive innovation, shaping the way healthcare professionals and technologies interact and evolve.
As she celebrates this milestone, Aviva remains committed to mentoring the next generation and fostering collaboration across the industry. Her legacy, intertwined with the LPBI Group’s contributions, will continue to inspire and lead the way in pharmaceutical intelligence and healthcare online education for years to come.
Looking to the future, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.
Beyond her professional achievements. As a mentor and collaborator, she has inspired a new generation of experts, nurturing their talents and guiding them towards new career goals reaching new heights. Cases-in-point are Adam Sonnenberg and Madison Davis (see their profile on LinkedIn and their roles at LPBI Group).
In the vast landscape of healthcare and pharmaceuticals, one name stands out as a beacon of innovation and expertise: Aviva Lev-Ari, PhD, RN. With a career, spanning for decades, Aviva has left an indelible mark on the e-Scientific Publishing industry, revolutionizing the way we approach electronic scientific publishing, knowledge communication and online education.
Born with an insatiable curiosity and a passion for understanding the intricacies of social sciences already in her high school years then intricacies of the healthcare field, in her 50s, Aviva embarked on an educational journey that would shape her future. From her early days at The Hebrew University of Jerusalem, where she earned her BA in 1973 and MA in 1976, a former student of Professor Louis Guttman, to her groundbreaking PhD in Industrial Organization Economics with a focus on corporate organizational aspects and Economic Geography at the University of California, Berkeley in 1983 where she was an advisee of Professor Allan Pred. Aviva’s thirst for knowledge knew no bounds. Along the way, she honed her skills at the Stanford University Graduate School of Business during an exchange program with UCB from 1980 to 1981 and studied with Professor James March.
Her career from 1985 to 2005 saw her working with some of the most notable organizations in various capacities. Among her employers during this period were:
- SRI, Menlo Park, CA: The largest Think Tank in the US with global reach, where Aviva served as Program Director, Business and Economic Statistics
- Amdahl Corporation, acquired by Fujitsu, Japan, where Aviva was a Senior Scientist, Lead, Demand Forecasting.
- Monitor Company, acquired by Deloitte, where Aviva worked as a Senior Consultant in Cambridge, MA, John Hancock account.
- MITRE, the most prestigious Federally Funded Research and Development Center (FFRDC), where Aviva was Head of Research of Economic and Decision Analysis Center (EDAC) in Bedford, MA.
- Perot Systems Corporation, acquired by Dell Technologies, where Aviva served as Director of Advanced Information Systems in Cambridge, MA.
- McGraw Hill, a global publisher, where Aviva was Director of Research Methods at CTB/McGraw-Hill in Monterey, CA.
25 years later she obtained her healthcare education and nursing credentials at Northeastern University’s Bouvé College of Health Sciences in 2007.
Armed with a formidable intellect and a visionary spirit, Aviva set out to transform the world of pharmaceutical intelligence in 2012 following five years in Clinical Nursing Management.
As the founder and director of the LPBI Group, launched in 4/2012, she created the BioMed e-Series, a cutting-edge e-learning platform that has empowered countless healthcare professionals to reach new heights in their careers. Through her role as Editor-in-Chief of Leaders in Pharmaceutical Business Intelligence, LPBI Group’s (a) Journal PharmaceuticalIntelligence.com and (b) BioMed e-Series Aviva has been at the forefront of electronic scientific publishing and content curation, driving innovation and fostering collaboration across the industry.
Aviva’s contributions to the field are nothing short of remarkable. With her extensive body of work, including numerous scientific articles, and e-books, she has shed light on critical topics such as cardiovascular diseases, pharmaco-genomics and cancer therapies. Her research interests span a wide range of disciplines, from medical, pharmaceutical, life sciences and scientific communications to health policy and healthcare delivery, showcasing her unwavering commitment to advancing the frontiers of knowledge by creation of curations that include creative interpretations of scientific findings.
The impact of Aviva’s work is evident in the impressive statistics of PharmaceuticalIntelligence.com, which, as of April 27, 2025, has garnered over 2,368,774 views and 1,506,446 visitors. The platform features 6,227 posts, of which 3,653 are curated by Aviva herself, reflecting the depth and breadth of her contributions. Aviva and her team at Leaders in Pharmaceutical Business Intelligence Group, LLC, doing business as LPBI Group, Newton, MA, have produced over 6,200 scientific articles (posts) and published 48 volumes, showcasing the extensive knowledge and expertise they bring to the field.
Her key team members include Larry H. Bernstein, MD, FACP, Justin D. Pearlman, MD, PhD, FACC, Stephen J. Williams, PhD, Tilda Barliya, PhD, Sudipta Saha, PhD, Dror Nir, PhD, Demet Sag, PhD, Ritu Saxena, PhD, Gail S Thornton, PhD (c), and Irina Robu, PhD. Together, they have created 48 volumes of e-books, with over 150,000 pages downloaded from these e-books on Amazon.com, showcasing the global reach and influence of their work. The BioMed e-Series, accessible at https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/ further exemplifies their commitment to providing comprehensive knowledge and educational resources.
Aviva’s multimedia approach to scientific communication is highlighted by the inclusion of 7,074 biological images, 302 podcasts, over 100 e-proceedings for biotech and medical conferences, and more than 50 tweet collections. These resources have enriched the learning experience for professionals worldwide, making complex scientific concepts more accessible and engaging.
The future looks bright, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage their expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.
As a mentor and collaborator, Aviva has inspired a new generation of experts, nurturing their talents and guiding them towards success in the Era of Artificial Intelligence and Medicine, Pharmaceutical, Healthcare and Life Sciences.
For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
APPENDIX
CV Format
https://www.linkedin.com/in/avivalevari/
Publication List
- Scientific and Medical Affairs Chronological CV
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
- HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
- Editorials & Publications of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence (LPBI) Group: Contributions by Aviva Lev-Ari, PhD, RN
- List of Invited Lectures, 1983 -2004
- List of Publications, 1983 – 2004
- List of Publications, 2006 – Present
- Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
- MedTech & Medical Devices for Cardiovascular Repair – Curations
- Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
- Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
- Cancer Research: Curations and Reporting
- Autobiographical Annotations: Tribute to My Professors
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
Updated on 7/12/2025
READ on the Legacy of LPBI Group as updated on 5/16/2025
- LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI
READ on Multimodal Healthcare Foundation Model as updated on 6/3/2025
- Multimodal Healthcare Foundation Model
Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert Content generated by LPBI Group’s Experts, Authors, Writers (EAWs) used as Training Data for the Model
https://pharmaceuticalintelligence.com/healthcare-foundation-model/
The Voice of Aviva Lev-Ari, 2.0 LPBI, Founder
Updated on 4/30/2025
UPDATED on 4/30/2025
Looking to the future, Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.
INTERACTIVE CHAT with Grok, created by xAI: LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director
For DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
Updated on 3/7/2024
The Portfolio of IP Digital Assets consists of the following ten (10) Asset Classes representing +7GB of data:
- Journal, 2.3MM views, 6200 articles, ~70% curations
- 48 e-Books: English-language Edition, Spanish-language Edition and five e-Series bundles for each language
https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
- 100 e-Proceedings & 50 Tweet collections of Biotech and Medical Conferences
- +8,000 biological Images
- +300 Audio Podcasts Library – Biological Sciences Discoveries in the 21stCentury
- +9300 subscribers to Pharmaceutical Intelligence
https://pharmaceuticalintelligence.com/
- Royalties for 145,000-page downloads
- Human Capital contributors Bio for 1,2,3,4,5, above
- Intangibles assets representing unparalleled e-Reputation of the Intellectual Property created
https://pharmaceuticalintelligence.com/intangibles-cim/Healthcare
- Composition of Methods: Workflows, SOPs, Protocols, Portals
Updated on 2/1/2024
For 2024 and 2025 we are adding qualifiers to 2.0 LPBI Group’s core competences and capabilities.
Our technologies are best described as the following:
- Company provides healthcare analytics
- Provider of cloud-based AI solutions, data and analysis platform and Analytics services for biological big data as e-Scientific Publisher for the life sciences industry, pharmaceutical industries and the healthcare sector
- AI platform to assist healthcare researchers
- Software for data driven discovery for the biotech industry
- Content in use for eDiscovery of context relationships and novel concepts
- Company specializing in medical text analysis for bio-analytical research, i.e., Synthetic Biology
- Provider of curated genomics information to support clinical genomic data interpretation
- Developer of AI-based platform for computational protein design
- Provider of AI-based drug discovery platform for oncology targeting Galectins
- Platform offering tech enabled intellectual property and a platform for development of IP as a service
- Developer of data management and visualization software for research and healthcare
- SaaS-based data visualization and analytics software for the healthcare industry
- Platform offering brand protection by creation of a library of biological images as Prior Art
- Provider of a research discovery platform with portal technology and audio podcast development
Updated on 2/1/2021
Milestone achieved today:
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Thought on the transition
One Possible Strategy for an Acquisition is via a SPAC
We are offering a unique opportunity to acquire the intellectual and physical assets of Leaders in Pharmaceutical Business Intelligence (LPBI), a scholarly enterprise that has pioneered the scientific curation of medical/pharmaceutical research. We anticipate revenues of $100MM over the next five years [Valuation of 2012-2020 Portfolio of IP and six pipelines to be pursued in 2021-2025.]
We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies:
https://pharmaceuticalintelligence.com/vision/
Our a portfolio of Intellectual Property Assets reaches 2MM e-Readers while offering 6,000 superior interpretive articles within five specialties of Medicine and Life Sciences.
We have created 16 books which have been downloaded ~125,000 times. LPBI researchers have covered in real time (both in writing and via Tweets) 100 of the top biotech and medical conferences over 8 years. All of LPBI’s content was created by our Experts, Authors, and Writers (EAWs).
LPBI is developing new strategies in AI and Blockchain technologies for application within LPBI’s content, for INSIGHT and pattern recognition by automated Machine Learning algorithms, to enhance drug discovery and drug repurposing,
LPBI’s vision for the coming five years includes:
- Content conversion by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds. Classification and clustering of concepts, context, processes and pathways.
- Conversion of our written content to Audio. We will convert English text to such foreign languages as Japanese, Spanish and Russian.
Three transformational transitions:
- From our current Open Access system, we will transition to Blockchain-based transaction networks.
- From Digital Cloud-based articles, we will create audio and video Podcasts
- From a sole owner-operator status, we will transition to Joint Ventures, M&A, and Partnerships
There are two strategic dimensions related this transformation:
- Our deep expertise and innovations in media platforms and content creation will have a new focus: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia
- Our created content will become the basis of our content mining, and the subject of managed computerized text analysis under supervised learning guided by our own team of experts
Strength of 2.0 LPBI
1. Strong scientific curation makes basic research readily available to wide range of scholars, practitioners and students in biomedical science
2. The books are convenient and comprehensive compendia of the latest scholarship.
3. The updating methodology keeps material current
4. Reporting on conferences and meetings gives the audience early access to the latest technologies in biomedicine
5. Curation methodology is transferable across disciplines and languages allowing for big international and interdisciplinary markets
6. The pricing analysis has been carefully researched across multimedia platforms
Our Ideas are Products of our Environment
The complex and rapid deluge of scientific information, absence of a collaborative, open environment to produce transformative innovation, and dearth of alternative ways to disseminate scientific findings has led to major operational inefficiencies in the biomedical and pharma industries, to the tune of millions of dollars per year. These issues have driven the need for a more context-driven architecture for knowledge and discourse within the biomedical arena. The process of curation decreases time for assessment of current trends adding multiple insights, analyses WITH an underlying METHODOLOGY, provides insights from WHOLE scientific community on multiple WEB 2.0 platforms, and makes use of new computational and Web-based tools to provide interoperability of data, reporting of findings.
At Leaders in Pharmaceutical Business Intelligence (LPBI) Group venture owner and Editor-in-Chief, Aviva Lev-Ari, PhD, RN has been developing a strategy for the
facilitation of Global access to Biomedical knowledge rather than the access to sheer search results on Scientific subject matters in the Life Sciences and Medicine”. According to Aviva, “for the methodology to attain this complex goal it is to be dealing with popularization of ORIGINAL Scientific Research via Content Curation of Scientific Research Results by Experts, Authors, Writers using the critical thinking process of expert interpretation of the original research results.
LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields. This curative process establishes new connections and produces new and transformative ideas.
Using our curation methodology, LPBI has produced an open-access online scientific journal, a series of 16 BioMed e-books, and Real-time press coverage of scientific conferences, all of which are optimally designed for novel Text Analysis methods using leading AI, ML and NLP algorithms from 3rd parties software applied on LPBI’s own content customizing the applications for the needs developed by LPBI in the classification and clustering of the Semantics in our contents: Journal articles (6,000) e-Books (16) Conferences content (100).
From our Past to our Future
Currently, there is a digital information explosion in both the Life Sciences and Medical arenas. Tracking new information and discoveries, while guarding against obsolescence, is a major issue for scientists working in these fields.
To overcome these challenges, the Leaders in Pharmaceutical Business Intelligence (LPBI) Group was created in 2012 by Dr. Aviva Lev-Ari.
LPBI (previously an equity sharing, non-profit entity) is now making its intellectual and digital intellectual properties available for sale to outside entities that are willing to take over and extend our reach.
Through use of AI, NLP, Audio Podcasts and additional advanced Machine Learning technologies, we are postulating revenues on the order of $50MM to the acquirer by exploiting our content [not including the valuation of 2012-2020 portfolio of IP.]
LPBI’s copyrighted curation process includes synthesis, analysis, and interpretation of complex medical and scientific areas by our highly trained and well-regarded staff. It creates vast, universally accessible scientific content, over multiple platforms within the Life Sciences, Medical, and Allied Health Care professional fields.
This enables the LPBI Group to respond to the needs of our scientific audiences, guarding against information obsolescence and overload, through innovative digital technologies and solutions, via:
- An open-access online scientific journal
- A series of 16 BioMed e-books.
- Real-time press coverage with real-time Twitter posting of speakers quotes during conferences.
These have been made widely available to the scientific and non-research community by the Open Access feature of LPBI’s Journal’s website PharmaceuticalIntelligence.com.
November 2020
2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
We describe below our vision for the evolution over the next five years of the existing pharmaceutical media venture, aka, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston. Our team members are in MA, NJ, India, CA, PA, Canada, ME and DE. Our web site is http://pharmaceuticalintelligence.com.
On January 2021, LPBI Group will transition from 1.0 LPBI to 2.0 LPBI. The description of 2.0 LPBI is included in the following three sources:
- https://pharmaceuticalintelligence.com/vision/
- https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/
- Three Sheets in an Excel file named MASTER_FINANCIALS-1.0-2.0-COMBINED.xlsx
2.0 LPBI Excel Spreadsheet – the financial prospects for LPBI for the future five years, as they represent new strategies for the existing ten IP Asset Classes developed since 2012 by the Founder and the Team of 1.0 LPBI.
Sheet #2
1.0 LPBI Group’s List of 10 IP Asset Classes described with Financial Revenue Potential in
Sheet #1
Combined 1.0 LPBI [(2012-2020) + (2021-2025)] and 2.0 LPBI [2021 – 2025] are exhibited in
Sheet #3
2.0 LPBI has developed transformational strategies for the natural progression from 1.0 LPBI Group’s List of 10 IP Asset Classes. These strategies are described below in detail.
2.0 LPBI Brochure
Contact for Access:
avivalev-ari@alum.berkeley.edu
2012pharmaceutical
sjwilliamspa
Leave a Reply